Cowen and Co. analyst Eric Schmidt summed up the sentiment of analysts on Biogen Inc.'s first-quarter financials, headlining a note on the company's "solid" performance with the observation that the spinal muscular atrophy (SMA) drug Spinraza (nusinersen) was "sprinting out of the gates."